In a phase 1b study, PXL70 inhibited liver adipogenesis and improved glucose metabolism and insulin sensitivity in patients with non-alcoholic fatty liver disease. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.